Liver Stiffness in Patients After the Fontan Procedure is Correlated with Age at Time of Surgery and Time since Surgery

Size: px
Start display at page:

Download "Liver Stiffness in Patients After the Fontan Procedure is Correlated with Age at Time of Surgery and Time since Surgery"

Transcription

1 Liver Stiffness in Patients After the Fontan Procedure is Correlated with Age at Time of Surgery and Time since Surgery Yuki Cho 1), Daisuke Tokuhara 1), Yuki Kawasaki 2), Eiji Ehara 2), Yosuke Murakami 2), Haruo Shintaku 1) 1) 2) Department of Pediatric Cardiology, Osaka City General Hospital, Japan

2 Background The Fontan procedure is a palliative thrapy for patients with congenital heart disease especially univentricullar heart. Over 400 cases/year in Japan. Thousands of patients who had undergone Fontan procedure. Fontan procedure led to an early mortality reduction.

3 Fontan Circulation Systemic Circulation Fontan Procedure Systemic Circulation Normal Circulation Liver RA RV LV LA Single Ventricule Lung Systemic Circulation Lung Univentricular Heart Liver Single Ventricule Liver Lung

4 Complications Plastic bronchitis Protein-losing enteropathy Poor somatic growth and development Liver dysfunction Normal Liver Delayed pubertal maturation Peripheral venous insufficiency Increased risk of thromboembolism Liver cirrhosis HCC * *:Hepatocellular carcinoma

5 Evaluation of liver fibrosis Liver Biopsy Laboratory Test Abdominal Ultrasonography GOLD STANDARD! Liver enzyme Fibrosis marker Invasiveness

6 Transient Elastography; FibroScan LSM (kpa) 30 Fibrosis Stage CAP (db/m) 400 Steatosis Grade ρ=0.920* 100 ρ=0.792* *:Spearman s rank correlation coefficient Cho.Y, et al. PLOS ONE, in press

7 Objectives To elucidate liver stiffness and hepatic fat deposition in patients who had undergone the Fontan procedure.

8 Patients Children were devided into 2 groups as following; Fontan group: Patients who had undergone the Fontan procedure Control group: Children without congenital heart malformation Patients with known liver disease and obesity(bmi percentile 90 ) were excluded from the control group

9 Methods (1) Abdominal ultrasonography, FibroScan, blood examination, anthropometry. (2) Comparison of LSM *1 and CAP *2 between 2 groups. (3) Correlation of LSM and CAP with AST, ALT, and age in both group. (4) Correlation of LSM and CAP with age at surgery, and time since surgery in Fontan group. *1 LSM, liver stiffness measurement *2 CAP, controlled attenuation parameter

10 Patient Profiles Control Fontan P value* N Male:Female 81:76 22: Age (year) 11.2 ± ± AST(IU/L) 23.2 ± ± 9.1 < ALT(IU/L) 17.4 ± ± 8.6 < Type 4 collagen (ng/ml) Hyaluronic Acid (ng/ml) 3.8 ± ± 1.8 < ± ± 38.3 = APRI ** 0.28 ± ± 0.23 < *:Mann-Whitney U-test **:APRI= AST/33 PLT[10 9 /L] 100

11 LSM (kpa) 50 Result :Control Age y.o

12 LSM (kpa) 50 Result p< * :Control :Fontan Age y.o *:Mann-Whitney U-test

13 CAP (db/m) 400 Result :Control Age y.o

14 CAP (db/m) 400 Result p= * :Control :Fontan Age y.o *:Mann-Whitney U-test

15 LSM (kpa) 50 Result ρ= * ρ= * ρ= * Age (y.o) Age at Surgery (y.o) Time after Surgery (y) *:Spearman s rank correlation coefficient

16 LSM (kpa) 50 Result ρ= * ρ= * (IU/L) (IU/L) AST ALT *:Spearman s rank correlation coefficient

17 LSM (kpa) 50 Result ρ= * ρ= * ρ= * Type 4 Collagen (ng/ml) Hyaluronic Acid (ng/ml) APRI *:Spearman s rank correlation coefficient

18 Discussion Fontan group showed higher LSM value than the Control group, and LSM was correlated with time after surgery whereas was not correlated with laboratory markers. Thus blood examination is insufficient to estimate severity of liver fibrosis in patients after Fontan operation. Most of patients after Fontan procedure receive anticoagulation therapy, so it is difficult to perform the liver biopsy because of risk of bleeding. Non-invasive evaluation method for liver fibrosis is necessary for the Fontan patients.

19 Conclusion Liver stiffness increases according to the time after Fontan surgery. FibroScan, the non-invasive elastography, is useful for measureing liver stiffness in patients after Fontan procedure.

Module 1 Introduction of hepatitis

Module 1 Introduction of hepatitis Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand

More information

Pretreatment Evaluation

Pretreatment Evaluation Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University

More information

Understanding your FibroScan Results

Understanding your FibroScan Results PATIENT & CAREGIVER EDUCATION Understanding your FibroScan Results This information will help you understand your FibroScan results. About FibroScan FibroScan is a specialized ultrasound machine for your

More information

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;

More information

Hepatology for the Nonhepatologist

Hepatology for the Nonhepatologist Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning

More information

Pretreatment Evaluation

Pretreatment Evaluation Pretreatment Evaluation Objective At the end of this lecture, the learner will be able to: Outline the appropriate evaluation of a person infected with HCV in order to assess the benefits and risks of

More information

Invasive. Sampling error. Interobserver variability. Nondynamic evaluation of

Invasive. Sampling error. Interobserver variability. Nondynamic evaluation of How to assess liver fibrosis Serum markers or FibroScan vs. liver biopsy? Laurent CASTERA & Pierre BEDOSSA Hôpital Beaujon, AP-HP, Clichy Université Paris-VII France 4 th Paris Hepatitis Conference, Paris,

More information

NON INVASIVE ASSESSMENT OF LIVER FIBROSIS : FIBROSCAN

NON INVASIVE ASSESSMENT OF LIVER FIBROSIS : FIBROSCAN NON INVASIVE ASSESSMENT OF LIVER FIBROSIS : FIBROSCAN M. Beaugrand Service d Hépatologied Hopital J. Verdier BONDY 93143 et Université Paris XIII MAINZ 21.09.2008 ASSESSMENT OF FIBROSIS : WHY? Management

More information

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. IV (June. 2017), PP 49-53 www.iosrjournals.org Assessment of Liver Stiffness by Transient

More information

Pretreatment Evaluation

Pretreatment Evaluation Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University

More information

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Objective Epidemiology Screening criteria Appropriate work up Treatment Guidelines

More information

Non-Invasive Testing for Liver Fibrosis

Non-Invasive Testing for Liver Fibrosis NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview

More information

Non-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology

Non-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology Non-Invasive Assessment of Liver Fibrosis Patricia Slev, PhD University of Utah Department of Pathology Disclosure Patricia Slev has no relevant financial relationships to disclose. 2 Chronic Liver Disease

More information

Transient elastography in chronic liver diseases of other etiologies

Transient elastography in chronic liver diseases of other etiologies 4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia

More information

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014 Cirrhosis Management for the Family Physician Mang Ma, MD, FRCP Professor University of Alberta Faculty: Mang Ma Faculty Disclosure Relationships with commercial interests: Advisory Board: Merck, Gilead

More information

NONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH

NONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH NONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH Bachir Taouli, MD Director of Body MRI and Cancer Imaging Program Department of Radiology / Translational and Molecular Imaging Institute

More information

Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty

Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty Supplementary Information Serum YKL- as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease Erina Kumagai 1,,#, Yohei Mano 1,#, Sachiyo Yoshio 1, Hirotaka Shoji 1, Masaya Sugiyama

More information

Clinical dilemmas in HBeAg-negative CHB

Clinical dilemmas in HBeAg-negative CHB Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department

More information

Preliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity

Preliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity Preliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity Dr. Katsutoshi Sugimoto Department of Gastroenterology and Hepatology, Tokyo Medical University, Japan Introduction

More information

What to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology

What to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology What to do about the high ALT picked up at the annual review Dr Michael Yee Consultant in Diabetes and Endocrinology Mrs DC HPC PMH Type 2 Diabetes (decades) Regular retinal screening No foot complications/neuropathy

More information

Diabetes Liver Screen

Diabetes Liver Screen YOUR LIVER AND YOUR HEALTH Diabetes Liver Screen Non-Alcoholic Fatty Liver Disease (NAFLD) PROF. SUZANNE NORRIS www.liverwellness.ie The spectrum of non-alcoholic fatty liver disease Diabetes Liver Screen

More information

LOGIQ S8 XDclear 2.0 Liver Procedures

LOGIQ S8 XDclear 2.0 Liver Procedures LOGIQ S8 XDclear 2.0 Liver Procedures See & quantify liver disease in a single exam Clinical Challenge Liver disease affects millions of people worldwide, and the number is growing. Clinicians need a cost-effective,

More information

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,

More information

WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT

WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT October 13, 2016 Reminder - treatment is recommended for all patients with chronic HCV infection Except short life expectancies that cannot be remediated

More information

Learning Objectives. After attending this presentation, participants will be able to:

Learning Objectives. After attending this presentation, participants will be able to: Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation

More information

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH Initial Evaluation for HCV Therapy Hope McGratty PA-C, MPH Conflict of Interest Disclosure Statement None Who are we talking about today? Treatment naïve Chronic infection This patient seems complicated

More information

In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease

In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general

More information

Medical Review Approaches to the Diagnosis of Liver Fibrosis

Medical Review Approaches to the Diagnosis of Liver Fibrosis Medical Review Approaches to the Diagnosis of Liver Fibrosis Hiroko Iijima Department of Hepatobiliary and Pancreatic Disease Ultrasound Imaging Center, Hyogo College of Medicine Hiroko Iijima Department

More information

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland Sanjiv Chopra, MD, MACP Professor of Medicine Harvard Medical School Editor In Chief Hepatology Section Up To Date Serum

More information

MR Elastography of Liver

MR Elastography of Liver MR Elastography of Liver Sudhakar K. Venkatesh, MD, FRCR Professor of Radiology Mayo Clinic College of Medicine Consultant, Abdominal Division Radiology, Mayo Clinic Rochester, MN, USA 19 th May 2018 2018

More information

Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning

Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning Presenter: Hersh Sagreiya 1, M.D. Authors: Alireza Akhbardeh 1, Ph.D., Isabelle Durot 1, M.D., Carlo Filice 2,

More information

Liver elastography ultrasound cpt code

Liver elastography ultrasound cpt code Liver elastography ultrasound cpt code In a multi-center study, Barbero-Villares et al (2012) evaluated the presence of significant liver fibrosis by transient elastography (FibroScan) in inflammatory.

More information

NON-ALCOHOLIC FATTY LIVER DISEASE:

NON-ALCOHOLIC FATTY LIVER DISEASE: NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF THE PRIMARY PROVIDER Archita P. Desai, MD Assistant Professor of Medicine University of Arizona 25 th Annual Southwestern Conference on Medicine Outline Pathophysiology

More information

INHSU th International Symposium on Hepatitis Care In Substance Users

INHSU th International Symposium on Hepatitis Care In Substance Users INHSU 2015 4 th International Symposium on Hepatitis Care In Substance Users Sydney, 7 October 2015 Non-invasive liver fibrosis assessment: Opportunities for enhanced liver disease assessment and treatment

More information

Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease

Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease Gut and Liver, Vol. 10, No. 2, March 2016, pp. 295-302 ORiginal Article Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic

More information

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,

More information

World Health Organization. Western Pacific Region

World Health Organization. Western Pacific Region Standard modules for HBV 1 HBV Module 1 Hepatitis B serological markers and virology 2 Acute hepatitis HAV HBV HCV HDV HEV Case fatality Case fatality Uncommon increases with increases with age age Superinfection

More information

PROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO

PROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO PROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO A. Giorgio Direttore del servizio di Ecografia Interventistica Istituto Clinico S.Rita -IRCCS -Atripalda (Avellino)

More information

Section 3: Testing and Diagnosis of Hepatitis C

Section 3: Testing and Diagnosis of Hepatitis C Section 3: Testing and Diagnosis of Hepatitis C Dr. Jules Alla Kouadio (Médecins du Monde) Training Hepatitis C and HR for PWUD, 20 th -24 th Sept. 2016, Nairobi, Kenya Learning objective of the session

More information

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,

More information

Screening cardiac patients for advanced liver disease

Screening cardiac patients for advanced liver disease HKASLD 30 th ASM and International Symposium on Hepatology 2017 Screening cardiac patients for advanced liver disease 5 Nov 2017 Dr. Lau Yue Leung Joulen Pamela Youde Nethersole Eastern Hospital NAFLD

More information

CASES FOR DISCUSSION. Yohannes B

CASES FOR DISCUSSION. Yohannes B CASES FOR DISCUSSION Yohannes B HCV CASE-1 A 34 years old apparently healthy lady who came to us after being told to have HCV infection on medical checkup done as part of a visa approval process to travel

More information

Original article On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients

Original article On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients Antiviral Therapy 2011; 16:165 172 (doi: 10.3851/IMP1726) Original article On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients Grace Lai-Hung Wong 1,2,

More information

Bio Predictive. FibroTest/FibroSure Scientific Publications. Houot 2015 FibroTest, TE, FIB-4, APRI Meta-analysis

Bio Predictive. FibroTest/FibroSure Scientific Publications. Houot 2015 FibroTest, TE, FIB-4, APRI Meta-analysis AASLD 2015 /FibroSure Scientific Publications Section 1 - compared to APRI, FIB-4 and transient elastography Houot 2015, TE, FIB-4, APRI Meta-analysis is superior to TE by Fibroscan, APRI and Fib-4 using

More information

JPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print

JPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print JPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print DOI : 10.1097/MPG.0000000000000489 Points to be considered when Applying FibroScan S Probe for Children with Biliary Atresia

More information

Meet the Professor: HIV/HCV Coinfection

Meet the Professor: HIV/HCV Coinfection Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University

More information

Liver Disease Assessment Among PWID: The Role of Transient Elastography

Liver Disease Assessment Among PWID: The Role of Transient Elastography Liver Disease Assessment Among PWID: The Role of Transient Elastography Peer Brehm Christensen, Professor Department of Infectious Diseases Odense University Hospital Denmark Peer.christensen@dadlnet.dk

More information

LONG TERM OUTCOMES OF PALLIATIVE CONGENITAL HEART DISEASE

LONG TERM OUTCOMES OF PALLIATIVE CONGENITAL HEART DISEASE LONG TERM OUTCOMES OF PALLIATIVE CONGENITAL HEART DISEASE S Bruce Greenberg, MD, FACR, FNASCI Professor of Radiology and Pediatrics Arkansas Children's Hospital University of Arkansas for Medical Sciences

More information

Original Article. Six Month Follow-up of Liver Stiffness Measurement in Untreated Chronic Hepatitis C With or Without HIV Co-infection

Original Article. Six Month Follow-up of Liver Stiffness Measurement in Untreated Chronic Hepatitis C With or Without HIV Co-infection Original Article Phrommee N, et al. 15 Six Month Follow-up of Liver Stiffness Measurement in Untreated Chronic Hepatitis C With or Without HIV Co-infection Phrommee N Leerapun A Pisespongsa P Chitapanarux

More information

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none

More information

Medical technologies guidance Published: 23 September 2015 nice.org.uk/guidance/mtg27

Medical technologies guidance Published: 23 September 2015 nice.org.uk/guidance/mtg27 Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C Medical technologies guidance Published: 23 September 2015 nice.org.uk/guidance/mtg27 NICE 2017. All rights

More information

New Tools for Assessing Disease Sererity, progression and regression in HBV and HCV

New Tools for Assessing Disease Sererity, progression and regression in HBV and HCV New Tools for Assessing Disease Sererity, progression and regression in HBV and HCV Jidong Jia, MD, PhD Beijing Friendship Hospital, Capital Medical University 2016-3-14 Disclosure Consultation for Abbvie

More information

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal

More information

HEPATITIS B: WHO AND WHEN TO TREAT?

HEPATITIS B: WHO AND WHEN TO TREAT? HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of

More information

When to Treat: Staging Liver Disease David L. Thomas, MD, MPH

When to Treat: Staging Liver Disease David L. Thomas, MD, MPH When to Treat: Staging Liver Disease David L. Thomas, MD, MPH Professor of Medicine Johns Hopkins School of Medicine Disclosures Received royalties from UpToDate, Inc. Staging refers to the assessment

More information

Hepatology For The Nonhepatologist

Hepatology For The Nonhepatologist Hepatology For The Nonhepatologist Andrew Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois Learning Objectives After attending this presentation, learners will be able

More information

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008 Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended

More information

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon

More information

Abstract and Introduction. Patients and Methods. M. Hedenstierna; A. Nangarhari; A. El-Sabini; O. Weiland; S.

Abstract and Introduction. Patients and Methods.   M. Hedenstierna; A. Nangarhari; A. El-Sabini; O. Weiland; S. www.medscape.com Cirrhosis, High Age and High Body Mass Index Are Risk Factors for Persisting Advanced Fibrosis After Sustained Virological Response in Chronic Hepatitis C M. Hedenstierna; A. Nangarhari;

More information

AASLD Immune tolerant phase HBV NAFLD diagnostic HCC

AASLD Immune tolerant phase HBV NAFLD diagnostic HCC AASLD 2016 Immune tolerant phase HBV NAFLD diagnostic HCC Immune tolerant 3 Modified from Chan HLY and Wong VWS. Hepatitis B. In Zakim and Boyers s Hepatology 2012 2015 AMERICAN ASSOCIATION FOR THE S1T6UDY

More information

Hepatitis C Update on New Treatments

Hepatitis C Update on New Treatments Hepatitis C Update on New Treatments Kevork M. Peltekian, MD, FRCPC 44th Annual Dalhousie Spring Refresher Course - Therapeutics April 5 - April 7, 2018 Halifax Convention Centre Disclosures Conflicts

More information

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Poster No.: C-3242 Congress: ECR 2010 Type: Topic: Authors: Keywords:

More information

HEP DART 2017, Kona, Hawaii

HEP DART 2017, Kona, Hawaii HEP DART 2017, Kona, Hawaii Rong Yu 1, Ke Xu 1, Jing Li 1, Tong Sun 1, Shengjiang Zhang 2, Jinhua Shao 2, Jin Sun 2, Qiong He 3, Jianwen Luo 3, Cheng Wang 4, Yudong Wang 4, Jing Chen 4, Vanessa Wu 4, George

More information

Liver 102: Injury and Healing

Liver 102: Injury and Healing Liver 102: Injury and Healing Dawn Pease, MSN, RN, ANP-BC Brackenridge Specialty Clinics University Medical Center Brackenridge Austin, TX Seton Healthcare Family Liver 102 Outline Biochemical patterns

More information

New York State HCV Provider Webinar Series

New York State HCV Provider Webinar Series New York State HCV Provider Webinar Series Overview of Fibrosis-Staging, Child s Pugh, MELD Scores Paul J Gaglio, MD, FACP, AGAF, FAASLD Director: Hepatology Outreach Professor of Medicine (in Surgery)

More information

Transient elastography the state of the art

Transient elastography the state of the art Transient elastography the state of the art Laurent CASTERA, MD PhD Department of Hepatology, Hôpital Beaujon, Clichy Université Paris-7, France White Nights of Hepatology, St Petersburg, Russia, june

More information

Noninvasive estimation of central venous pressure after Fontan procedure using biochemical markers and abdominal echography

Noninvasive estimation of central venous pressure after Fontan procedure using biochemical markers and abdominal echography Noninvasive estimation of central venous pressure after Fontan procedure using biochemical markers and abdominal echography Tatsujiro Oka, MD, PhD, a Ryuichi Kato, MD, a Shigehisa Fumino, MD, PhD, b Kentaro

More information

A serum sweet-doughnut protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis

A serum sweet-doughnut protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis Supplementary information A serum sweet-doughnut protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis Atsushi Kuno 1#, Yuzuru Ikehara 1#, Yasuhito Tanaka, Kiyoaki

More information

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012 NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat

More information

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Poster No.: C-3242 Congress: ECR 2010 Type: Topic: Authors: Keywords:

More information

Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis

Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis Alina M. Allen, Meng Yin, Sudhakar K. Venkatesh, Taofic Mounajjed, Todd A. Kellogg,

More information

Non-invasive diagnostic biomarkers

Non-invasive diagnostic biomarkers Non-invasive diagnostic biomarkers Liver Forum, November 12 th, 2015 Rohit Loomba, MD, MHSc Professor of Medicine (with tenure) Director, NAFLD Research Center, Division of Gastroenterology, Department

More information

Screening for HCCwho,

Screening for HCCwho, Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology

More information

Emerging Challenges In Primary Care: 2015

Emerging Challenges In Primary Care: 2015 Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor of Clinical

More information

Emerging Challenges In Primary Care: Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, and How

Emerging Challenges In Primary Care: Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, and How Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, and How 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor

More information

Screening for Portal Hypertension in Cirrhosis

Screening for Portal Hypertension in Cirrhosis Screening for Portal Hypertension in Cirrhosis MASSIMO PINZANI, MD, PhD, FRCP Sheila Sherlock Chair of Hepatology UCL Institute for Liver and Digestive Health Royal Free Hospital, London, UK m.pinzani@ucl.ac.uk

More information

Emerging Challenges In Primary Care: 2015

Emerging Challenges In Primary Care: 2015 Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor of Clinical

More information

NON INVASIVE EVALUATION OF DISEASE PROGRESSION IN CHRONIC LIVER DISEASES

NON INVASIVE EVALUATION OF DISEASE PROGRESSION IN CHRONIC LIVER DISEASES Best of EASL -, Ethiopia 29 Sep to 01 Oct, 2016 Inaugural meeting of the Sub Saharan GI-Hepatology Working Group Incorporating Best of AGA and Best of EASL NON INVASIVE EVALUATION OF DISEASE PROGRESSION

More information

Management of Liver Diseases: A Nonhepatologist s Viewpoint

Management of Liver Diseases: A Nonhepatologist s Viewpoint Management of Liver Diseases: A Nonhepatologist s Viewpoint Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston,

More information

Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD

Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis

More information

*APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor

*APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor APPENDIX 1 LIST OF COINVESTIGATORS *APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor M Vidaud; Hôpital Cochin-Necker: Professor S Pol, Professor Ph Sogni, Professor

More information

Patients must have met all of the following inclusion criteria to be eligible for participation in this study.

Patients must have met all of the following inclusion criteria to be eligible for participation in this study. Supplementary Appendix S1: Detailed inclusion/exclusion criteria Patients must have met all of the following inclusion criteria to be eligible for participation in this study. Inclusion Criteria 1) Willing

More information

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment

More information

Diagnostic value of various noninvasive indexes in the diagnosis of chronic hepatic fibrosis

Diagnostic value of various noninvasive indexes in the diagnosis of chronic hepatic fibrosis European Review for Medical and Pharmacological Sciences 2018; 22: 479-485 Diagnostic value of various noninvasive indexes in the diagnosis of chronic hepatic fibrosis X.-Z. YANG, A.-W. GEN, J.-C. XIAN,

More information

Radiology Update 2017

Radiology Update 2017 Radiology Update 2017 John K. Phillips, MD Affiliated Assistant Professor of Radiology University of Tennessee Health Sciences Center Chief, Radiology and Nuclear Medicine VA Memphis Disclosures Financial:

More information

NAFLD and NASH: The Not-So-New Kids on the Block

NAFLD and NASH: The Not-So-New Kids on the Block NAFLD and NASH: The Not-So-New Kids on the Block Mary E. Rinella, MD Associate Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Illinois This program is supported by an

More information

THE ROLE OF TRANSIENT ELASTOGRAPHY IN THE DIAGNOSIS OF LIVER FIBROSIS AND PORTAL HYPERTENSION

THE ROLE OF TRANSIENT ELASTOGRAPHY IN THE DIAGNOSIS OF LIVER FIBROSIS AND PORTAL HYPERTENSION LITHUANIAN UNIVERSITY OF HEALTH SCIENCES MEDICAL ACADEMY Romanas Zykus THE ROLE OF TRANSIENT ELASTOGRAPHY IN THE DIAGNOSIS OF LIVER FIBROSIS AND PORTAL HYPERTENSION Doctoral Dissertation Biomedical Sciences,

More information

HEPATIC ELASTOGRAPHY AND FIB-4 SCORE VERSUS LIVER BIOPSY FOR ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV PATIENTS

HEPATIC ELASTOGRAPHY AND FIB-4 SCORE VERSUS LIVER BIOPSY FOR ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV PATIENTS HEPATIC ELASTOGRAPHY AND FIB-4 SCORE VERSUS LIVER BIOPSY FOR ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV PATIENTS Essam A. Wahab*, Talaat Fathy** Sameh Saber*** and Hanan S. Ahmad**** Internal Medicine*,

More information

Bio Predictive. FibroTest/FibroSure Scientific Publications Posters for AASLD 2013 #999! FibroTest HBV. Sun, Nov 03 8:00 AM AASLD

Bio Predictive. FibroTest/FibroSure Scientific Publications Posters for AASLD 2013 #999! FibroTest HBV. Sun, Nov 03 8:00 AM AASLD AASLD #999 HBV Sun, Nov 03 FibroTest/FibroSure Scientific Publications Posters for AASLD 2-years impact of entecavir (ETV) on liver fibrosis and activity as assessed by the non-invasive methods of FibroTest-ActiTest

More information

Liver stiffness predicts liver related events and mortality in HIV/HCV coinfected patients

Liver stiffness predicts liver related events and mortality in HIV/HCV coinfected patients Liver stiffness predicts liver related events and mortality in HIV/HCV coinfected patients José Vicente Fernández-Montero, Pablo Barreiro, Eugenia Vispo, Pablo Labarga, Francisco Blanco, Fernanda Rick,

More information

UMHS-PUHSC JOINT INSTITUTE

UMHS-PUHSC JOINT INSTITUTE Role of Visceral Adiposity in the Pathogenesis of Non-Alcoholic Fatty Liver Disease in Lean versus Obese Patients: A Comparative Study between Patients at UMHS versus PUHSC Lai WEI and Anna LOK W Zhang,

More information

Non-Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the

More information

Hepatocellular Carcinoma: Epidemiology and Screening

Hepatocellular Carcinoma: Epidemiology and Screening Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman

More information

Acoustic radiation force impulse elastography in distinguishing hepatic haemangiomata from metastases: preliminary observations

Acoustic radiation force impulse elastography in distinguishing hepatic haemangiomata from metastases: preliminary observations The British Journal of Radiology, 84 (2011), 939 943 SHORT COMMUNICATION Acoustic radiation force impulse elastography in distinguishing hepatic haemangiomata from metastases: preliminary observations

More information

Transient elastography in chronic viral liver diseases

Transient elastography in chronic viral liver diseases 4 th AISF POST-MEETING COURSE Roma, 26 Febbraio 2011 Transient elastography in chronic viral liver diseases CRISTINA RIGAMONTI, M.D., Ph.D. Transient elastography (TE): a rapid, non-invasive technique

More information

Who to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat

Who to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor

More information

World Health Organization. Western Pacific Region

World Health Organization. Western Pacific Region Basic modules for HCV 1 HCV Module 1 Hepatitis C serological markers and virology 2 HCV Markers 3 Test Anti HCV (Anti hepatitis C virus antibody) HCV RNA (quantitative or qualitative) (Nucleic acid test)

More information

Research Article Assessment of Liver Stiffness in Pediatric Fontan Patients Using Transient Elastography

Research Article Assessment of Liver Stiffness in Pediatric Fontan Patients Using Transient Elastography Canadian Gastroenterology and Hepatology Volume 2016, Article ID 7125193, 7 pages http://dx.doi.org/10.1155/2016/7125193 Research Article Assessment of Liver Stiffness in Pediatric Fontan Patients Using

More information

5/2/2016. Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital Boston, Massachusetts

5/2/2016. Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital Boston, Massachusetts Management of Liver Diseases (A Nonhepatologist s Viewpoint) Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital Boston, Massachusetts FINAL: 04/11/2016

More information

Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18

Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis

More information